Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript

🌐 Seeking Alpha (United States) —

AI Summary

Mirum Pharmaceuticals discussed Phase 3 EXPAND study results for maralixibat in patients with cholestatic pruritus, including those with biliary atresia. The article is a transcript of the company’s discussion; the provided information does not specify the results.

Markets Health Mirum Pharmaceuticals maralixibat Phase 3 EXPAND study cholestatic pruritus biliary atresia

Read original source →